Tirzepatide vs Retatrutide

TL;DR

• Tirzepatide is a dual agonist — it activates GLP-1 and GIP receptors. FDA-approved (Mounjaro / Zepbound).
• Retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors. Still in clinical trials, not yet FDA-approved.
• The shorthand: tirzepatide is current-gen with regulatory approval. Retatrutide is next-gen with bigger weight-loss numbers but no approval yet.

If you only remember one thing: retatrutide adds glucagon receptor agonism, which sounds counterintuitive but actually drives more energy expenditure. Bigger total weight-loss numbers in trials.

The headline difference, in one sentence

Tirzepatide pulls two metabolic levers. Retatrutide pulls three — adding glucagon, which sounds wrong but increases energy expenditure on top of appetite suppression.

What each one is

Retatrutide's trial data, while preliminary, has produced the largest weight-loss numbers of any incretin therapy yet studied.

Pick tirzepatide if...

• You want a regulated, prescribable, well-characterized option with multi-year safety data.
• The research target is standard weight-loss or diabetes outcomes that current trials cover.
• You need insurance coverage or pharmacy access — retatrutide isn't there yet.
• You want a compound with defined dosing protocols rather than evolving research-stage regimens.

Pick retatrutide if...

• You're researching maximum-effect weight-loss outcomes and the increased efficacy is worth the unapproved status.
• You want to study glucagon receptor agonism specifically — retatrutide is currently the only available triple agonist.
• You're comfortable with bleeding-edge research compounds that lack the long-tail safety data of approved drugs.
• You're researching energy-expenditure mechanisms alongside appetite suppression — the glucagon component is studied for resting metabolic rate effects.

Why adding glucagon sounds wrong but actually works

Glucagon is the hormone that raises blood sugar by signaling the liver to release stored glucose. So adding a glucagon agonist to a weight-loss drug sounds backwards — wouldn't that raise blood sugar and undermine the GLP-1 effect?

In practice, glucagon receptor agonism in this context produces:

• Increased energy expenditure — the body burns more calories at rest
• Improved liver fat handling — relevant for NAFLD/NASH research
• A counterbalance to GLP-1's pure appetite suppression with an active metabolic-rate component

The GLP-1 component still suppresses appetite. The GIP component still helps with insulin handling. The glucagon component adds calorie burn. Net result in trials: more weight loss than dual-agonism alone.

Honest tradeoffs

• Safety data: tirzepatide has multi-year FDA-monitored data. Retatrutide does not. Rare adverse events that take years to surface haven't had time to surface.
• Side effects: both produce GI side effects (nausea, vomiting, diarrhea), often more pronounced during titration. Retatrutide trials have shown comparable or slightly higher GI rates at top doses.
• Cardiovascular profile: GLP-1/GIP agonists generally have favorable cardiovascular outcomes data. Glucagon agonism's long-term cardiac profile is less mature.
• Lean mass loss: bigger total weight loss means bigger absolute lean mass loss without protein and resistance training counter-strategies. This applies to both, more pronounced with retatrutide simply because the total loss is larger.
• Discontinuation regain: both compounds, like all current incretin-class therapies, are associated with weight regain after discontinuation.
• Compounding/research supply: retatrutide compounding is available in research-supply channels but the regulatory landscape is shifting fast. Tirzepatide compounding has tightened in many jurisdictions.

Quick decision shortcut

Where to read more

• Full breakdown of Tirzepatide.
• Full breakdown of Retatrutide.
• The earlier comparison: Semaglutide vs Tirzepatide.

Important context

Tirzepatide is an FDA-approved prescription medication. Retatrutide is investigational and not approved for any indication. Compounded research-supply versions exist but vary in regulatory status by jurisdiction. Both compounds have meaningful side-effect profiles, contraindications, and monitoring requirements. Nothing on this page is medical advice.